From: Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting
Drug | Regimen Backbone | Indication | Mechanism | References |
---|---|---|---|---|
Magrolimab | AZA/VEN | ND AML | Anti-CD47 antibody | [6] |
Gilteritinib | AZA/VEN | ND and R/R AML | FLT3 inhibitor | [7] |
SNDX-5613 (Revumenib) | N/A | R/R AML | Menin inhibitor | [3] |
KO-539 (Ziftomenib) | N/A | R/R AML | Menin inhibitor | [4] |
Pivekimab sunirine (PVEK) | AZA/VEN | R/R AML | Antibody–drug conjugate targeting CD123 | [5] |